BR112017023951A2 - derivados de etinila - Google Patents
derivados de etinilaInfo
- Publication number
- BR112017023951A2 BR112017023951A2 BR112017023951-5A BR112017023951A BR112017023951A2 BR 112017023951 A2 BR112017023951 A2 BR 112017023951A2 BR 112017023951 A BR112017023951 A BR 112017023951A BR 112017023951 A2 BR112017023951 A2 BR 112017023951A2
- Authority
- BR
- Brazil
- Prior art keywords
- lower alkyl
- halogen
- substituted
- pyridinyl
- pyrimidinyl
- Prior art date
Links
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15179550 | 2015-08-03 | ||
| EP15179550.7 | 2015-08-03 | ||
| PCT/EP2016/068359 WO2017021384A1 (en) | 2015-08-03 | 2016-08-02 | Ethynyl derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017023951A2 true BR112017023951A2 (pt) | 2018-07-24 |
Family
ID=53776452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017023951-5A BR112017023951A2 (pt) | 2015-08-03 | 2016-08-02 | derivados de etinila |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10011607B2 (https=) |
| EP (1) | EP3331882B1 (https=) |
| JP (1) | JP6975511B2 (https=) |
| KR (1) | KR20180030857A (https=) |
| CN (1) | CN107667107B (https=) |
| AR (1) | AR105556A1 (https=) |
| AU (1) | AU2016302696B2 (https=) |
| BR (1) | BR112017023951A2 (https=) |
| CA (1) | CA2983908A1 (https=) |
| CL (1) | CL2018000278A1 (https=) |
| CO (1) | CO2017011010A2 (https=) |
| IL (1) | IL255103B (https=) |
| MX (1) | MX2018001486A (https=) |
| PE (1) | PE20180357A1 (https=) |
| PH (1) | PH12018500247A1 (https=) |
| RU (1) | RU2722014C9 (https=) |
| TW (1) | TWI621619B (https=) |
| UA (1) | UA120888C2 (https=) |
| WO (1) | WO2017021384A1 (https=) |
| ZA (1) | ZA201707015B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20181366A1 (es) | 2015-08-03 | 2018-08-27 | Bristol Myers Squibb Co | Compuestos heterociclicos utiles como moduladores de factor de necrosis tumoral (tnf) alfa |
| CN108026050B (zh) | 2015-08-03 | 2021-04-30 | 格兰马克药品股份有限公司 | 作为RORγ调节剂的新型化合物 |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| AR117469A1 (es) | 2018-12-21 | 2021-08-11 | Merck Patent Gmbh | Derivados de alquino disustituidos |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012010738A2 (pt) * | 2009-11-06 | 2019-09-24 | Univ Vanderbilt | ''aril e heteroaril sulfonas como potenciadores alostéricos de mglur4,composições e métodos de tratamento de disfunção neurológica'' |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| CA2829171C (en) * | 2011-04-26 | 2019-02-26 | F. Hoffmann-La Roche Ag | Pyrazolidin-3-one derivatives |
| EP3049409B1 (en) * | 2013-09-25 | 2017-05-03 | F. Hoffmann-La Roche AG | Ethynyl derivatives |
| TWI649310B (zh) * | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
| MA39305A3 (fr) * | 2014-02-25 | 2018-05-31 | Hoffmann La Roche | Dérivés d'éthynyle |
-
2016
- 2016-08-01 AR ARP160102335A patent/AR105556A1/es unknown
- 2016-08-02 BR BR112017023951-5A patent/BR112017023951A2/pt not_active Application Discontinuation
- 2016-08-02 UA UAA201801410A patent/UA120888C2/uk unknown
- 2016-08-02 CN CN201680029481.6A patent/CN107667107B/zh not_active Expired - Fee Related
- 2016-08-02 PE PE2017002405A patent/PE20180357A1/es unknown
- 2016-08-02 AU AU2016302696A patent/AU2016302696B2/en not_active Ceased
- 2016-08-02 WO PCT/EP2016/068359 patent/WO2017021384A1/en not_active Ceased
- 2016-08-02 CA CA2983908A patent/CA2983908A1/en not_active Abandoned
- 2016-08-02 RU RU2018105872A patent/RU2722014C9/ru active
- 2016-08-02 KR KR1020187003005A patent/KR20180030857A/ko not_active Ceased
- 2016-08-02 MX MX2018001486A patent/MX2018001486A/es active IP Right Grant
- 2016-08-02 EP EP16745473.5A patent/EP3331882B1/en active Active
- 2016-08-02 TW TW105124484A patent/TWI621619B/zh not_active IP Right Cessation
- 2016-08-02 JP JP2018505431A patent/JP6975511B2/ja not_active Expired - Fee Related
-
2017
- 2017-10-17 ZA ZA2017/07015A patent/ZA201707015B/en unknown
- 2017-10-18 IL IL255103A patent/IL255103B/en active IP Right Grant
- 2017-10-27 CO CONC2017/0011010A patent/CO2017011010A2/es unknown
-
2018
- 2018-01-10 US US15/867,097 patent/US10011607B2/en active Active
- 2018-01-31 CL CL2018000278A patent/CL2018000278A1/es unknown
- 2018-02-01 PH PH12018500247A patent/PH12018500247A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3331882A1 (en) | 2018-06-13 |
| CN107667107B (zh) | 2021-05-18 |
| EP3331882B1 (en) | 2020-04-29 |
| UA120888C2 (uk) | 2020-02-25 |
| IL255103B (en) | 2020-01-30 |
| RU2722014C9 (ru) | 2020-10-22 |
| AU2016302696A1 (en) | 2017-11-02 |
| JP2018522037A (ja) | 2018-08-09 |
| US10011607B2 (en) | 2018-07-03 |
| CO2017011010A2 (es) | 2018-02-09 |
| ZA201707015B (en) | 2018-11-28 |
| IL255103A0 (en) | 2017-12-31 |
| US20180127429A1 (en) | 2018-05-10 |
| HK1246790A1 (zh) | 2018-09-14 |
| CN107667107A (zh) | 2018-02-06 |
| RU2722014C2 (ru) | 2020-05-26 |
| MX2018001486A (es) | 2018-03-15 |
| AU2016302696B2 (en) | 2020-05-07 |
| CL2018000278A1 (es) | 2018-07-06 |
| WO2017021384A1 (en) | 2017-02-09 |
| PH12018500247A1 (en) | 2018-08-13 |
| RU2018105872A3 (https=) | 2019-12-26 |
| TW201718589A (zh) | 2017-06-01 |
| KR20180030857A (ko) | 2018-03-26 |
| TWI621619B (zh) | 2018-04-21 |
| CA2983908A1 (en) | 2017-02-09 |
| RU2018105872A (ru) | 2019-09-05 |
| JP6975511B2 (ja) | 2021-12-01 |
| AR105556A1 (es) | 2017-10-18 |
| PE20180357A1 (es) | 2018-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500106A1 (en) | Ethynyl derivatives as metabotropic glutamate receptor modulators | |
| PE20230834A1 (es) | Antagonistas del receptor de lpa y usos de los mismos | |
| BR112017023951A2 (pt) | derivados de etinila | |
| BR112015005186A2 (pt) | 2-oxo-2,3-di-hidro-indóis para tratamento de distúrbios do snc | |
| PE20220253A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| BR112016010168A2 (pt) | derivados de etinil-imidazolina-2,4-diona como moduladores de mglur4 | |
| PH12012500690A1 (en) | Positive allosteric modulators (pam) | |
| BR112013021848A2 (pt) | 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina-carboxamidas como moduladores de mglur5 | |
| BR112014015832A2 (pt) | derivados heterocíclicos como receptores associados com aminas vistigiais (taars) | |
| PH12016500427A1 (en) | Ethynyl derivatives | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| EA200970911A1 (ru) | Хинолины и их терапевтическое применение | |
| BR112016017816A8 (pt) | derivados de etinila, seus usos, e composição farmacêutica | |
| AR104863A1 (es) | Derivados imidazol | |
| AR103952A1 (es) | Derivados de pirimidina-diona | |
| BR112019000314A2 (pt) | derivados de etinila | |
| AR105327A1 (es) | Derivados de imidazol | |
| BR112015009990A2 (pt) | derivados de pirazina | |
| BR112015002921A2 (pt) | derivados de ariletinila. | |
| TH1701007645A (th) | อนุพันธ์เอไทนิล | |
| TH1701007595A (th) | อนุพันธ์เอไทนิลในฐานะโมดูเลเตอร์ของเมทาโบโทรปิกกลูตาเมตรีเซปเตอร์ | |
| AR102599A1 (es) | 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| BR112012032576A2 (pt) | derivados de amino-tropano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |